Services Products & Reviews

The Agilent SurePrint platform delivers high-quality oligo pools perfectly suited for applications in protein engineering, gene assembly, pooled CRISPR screening, and more. Agilent oligo pools offer custom, high resolution, massively parallel DNA synthesis available in standard or HiFi options in a broad range of sizes.

For the Roche Digital LightCycler® System

The oligos are made to your specifications, with rigorous quality control, and quick turnaround for use in a variety of applications, including PCR, cloning, sequencing, and gene detection. Use the improved ordering portal to place your orders.  

Double-stranded DNA fragments for high-throughput screening applications

Custom DNA oligos—manufactured and shipped the same day you order

Bioneer’s core competency in delivering the most rigorously manufactured nucleic acids, includes providing the industry’s highest quality Custom RNA oligos. To cover all of your bases, we manufacture RNA oligos with our patented Bio-RP purification which approaches near HPLC quality. For your most stringent applications, we offer a wide array of modification options and services including bar-code labeling and annealing chimer…

Oligonucleotide GMP manufacturing for human therapeutics

Semiconductor-based 8 million oligos per chip with superior precision and consistency.

Our Metabolite Identification service employs HRMS /LC-MS/MS to decode degradation pathways of antisense oligonucleotides (ASOs), siRNAs, and modified variants, identifying chain-shortened metabolites (5’/3’ cleavage), phosphorothioate changes (desulfurization, inversion) and base/nucleotide alterations (deamination/depurination). Through plasma/tissue/cell analysis, we reveal metabolic stability, biodistribution, and exonucle…

Creative Biolabs delivers an end-to-end CAR-T development pathway—from target/scFv discovery, CAR design and vectoring, and cell engineering to in-vitro/in-vivo efficacy, IND authoring, and manufacturing support. Modular and GMP-aligned, the platform spans autologous and allogeneic routes (incl. TRAC/Cas9 and mRNA) to de-risk translation for hematologic and solid tumor programs.

End‑to‑end TCR‑like antibody services targeting peptide–MHC complexes—covering immunogen design, pMHC screening, affinity maturation, developability optimization, and functional validation—with output as IgG, bispecifics, or CAR constructs to access intracellular‑derived antigens.

End‑to‑end solid‑tumor CAR‑T development—from antigen/scFv discovery and CAR optimization to cell engineering, in‑vitro/in‑vivo efficacy, and IND support. Incorporates dual/logic‑gated and armored CARs, plus trafficking and persistence enhancements to overcome the tumor microenvironment and improve safety and translation.

Tailored formulation and conjugation for nucleic acids and biologics, covering LNPs and alternative carriers, ligand-directed strategies (e.g., GalNAc), and full characterization and process development to enhance stability, targeting, and potency with documentation for scale-up and regulatory needs.

Custom DNA/RNA oligonucleotide synthesis with broad modification choices (PS, 2′-OMe, 2′-F, LNA, GalNAc, dyes/biotin), multiple scales and purifications, and analytical QC. Includes design consultation and documentation to support research, translational studies, and conjugation-ready formats.

Integrated ASO development from sequence design and chemistry selection to preclinical PK/PD, safety, delivery (e.g., GalNAc), and CMC—supporting gapmer and steric-blocker approaches to advance programs efficiently toward IND.

End‑to‑end allogeneic cell therapy development—covering donor strategy, multiplex genome editing for safety/immune evasion, scalable manufacturing and comparability, and IND/CMC support—across CAR‑T/CAR‑NK and other donor‑derived modalities to enable off‑the‑shelf access.

Configurable TIL therapy development spanning tumor processing, TIL isolation/rapid expansion, functional and phenotypic qualification, and release criteria—paired with manufacturing‑aligned process development and IND documentation to de‑risk scale‑up for solid‑tumor programs.

Comprehensive circRNA services including design, circularization (e.g., ribozyme/intron-mediated), purification, and analytics to deliver stable, translation-competent RNA with improved durability—supported by process development for research and translational programs.

End-to-end viral vector design and construction covering vector/serotype selection, expression-cassette optimization, cloning, packaging, purification, and QC. Supports AAV, lentivirus, adenovirus, HSV, vaccinia, and baculovirus with scalable production and documentation for in vitro/in vivo studies and IND-enabling work.

The Transcreener dAMP Exonuclease Assay directly measures dAMP produced by exonuclease enzymes as they cleave polynucleotides. 

High-quality and cost-effective custom RNA oligos up to 266 nt, featuring comprehensive modifications.

High-quality and cost-effective custom DNA oligos up to 218 nt, backed by over 22 years of experience.

Stable Isotope-labeled Standards for Glycan Research

Stable Isotope-labeled RNA and DNA Products

For Mpox qPCR assay development